Navigating the Evolving Paradigms in the Diagnosis and Treatment of Myeloproliferative Disorders
|
|
- Clemence Fitzgerald
- 6 years ago
- Views:
Transcription
1 Navigating the Evolving Paradigms in the Diagnosis and Treatment of Myeloproliferative Disorders Ruben A. Mesa Associate Professor of Medicine, Division of Hematology, Mayo Clinic; Rochester, MN US The diagnosis and management of the BCR-ABL negative myeloproliferative disorders (MPDs) of polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are at an explosive crossroads of scientific investigation and evolving paradigms since the discovery of the tyrosine kinase activating JAK2V617F mutation in Additional discovery of relevant molecular lesions (JAK2 exon 12 mutations and c-mplw515l/k) have only further enriched our understanding of MPD pathogenesis. The improved diagnostic certainty these molecular markers provide have resulted in the modification, and simplification, of the World Health Organization (WHO) diagnostic algorithms for MPDs. Despite these scientific advances, however, the initial management of MPDs continues to rely upon a riskbased strategy to minimize the risk of vascular events with control of erythrocytosis, targeted antiplatelet therapy, and risk-based myelosuppressive therapy. No current medical therapy has altered the natural trend of the MPDs to lead to overt severe myelofibrosis or acute leukemia. Investigations into targeted therapies for MPDs are proceeding at a brisk pace with agents aimed at immunomodulation, decreasing marrow stromal reaction to the aberrant clone, DNA hypomethylation, or the inhibition of tyrosine kinases. Specific inhibition of JAK2 itself appears promising by in vitro investigations, and clinical trials with multiple agents are planned to commence enrollment in The potential impact of JAK2 inhibitors on the manifestations of the MPDs is unclear, but is awaited with great interest. From Dameshek to WHO: What Constitutes an MPD Today? The BCR-ABL negative chronic myeloproliferative disorders (MPDs), first described by William Dameshek in 1951, 1 are currently in a period of rapid discovery regarding their pathogenetic mechanisms. This period of rapid improvement of mechanistic understanding is likewise leading to similar changes in diagnostic criteria and hopefully improved targeted therapies. The MPDs have classically included the disorders of polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), yet even our preconceived understanding of the diagnostic and therapeutic differences between these disorders are evolving rapidly. This manuscript will try to outline the effect the evolving understanding of MPD pathogenesis is having the clinical care of patients with MPD. The watershed moment for MPDs occurred in 2005 with the heavily publicized discovery of the JAK2V617F mutation. 2-5 This point mutation, in the pseudokinase domain of JAK2 (a key component of the cell growth and differentiation JAK-STAT pathway), leads to constitutive activation of the pathway. This mutation joined the pantheon of constitutively active tyrosine kinases identified as playing a role in myeloid neoplasms, including BCR- ABL in chronic myeloid leukemia, FIP1L1-PDGFRA for chronic eosinophilic leukemia and systemic mastocytosis, and KITD816V for systemic mastocytosis, among many others. 6 The impact has been such that a search of PubMed for the 24 months prior to the JAK2V617F discovery reveals 520 manuscripts for myeloproliferative disorder and 380 manuscripts for JAK2, whereas 715 and 682 manuscripts were identified in the subsequent 24 months for myeloproliferative disorder and JAK2, respectively. This flurry of investigative activity has lead to the discovery of additional genetic mutations with potential pathogenetic implications including the c-mplw515l/k (in 5% of PMF and 1% of ET) 7 and alternative mutations in the exon 12 of JAK2 in some of those patients with PV previously identified as wild type for JAK2. 8 So, what is the effect of our improved understanding of MPD biology on the diagnostic process? The diagnosis of the BCR-ABL negative MPDs has always been limited by the absence of a gold standard, an absolute molecular marker. This latter deficiency has led to a series of clinico-pathologic diagnostic criteria relying upon features helpful in distinguishing an MPD from (1) a reactive state; (2) an alternative myeloid malignancy; and (3) an alternative MPD diagnosis. These criteria usually were the easiest to apply to overt MPD cases, but not uncommonly would leave others with uncertainty. The World Health Organization (WHO) has taken a lead role in diagnostic criteria for MPDs, and the current WHO criteria 9 for PV, ET, and PMF are undergoing a revision 10 to incorporate the diagnostic implications of the new wave of mutations (such as the JAK2V617F) (Figure 1). Hematology
2 Polycythemia vera PV is the MPD in which the presence of the JAK2V617F is of greatest diagnostic importance because it is seen well in excess of 90% of afflicted individuals. 2-5 Many of the patients who clinically have PV yet have wild-type JAK2 may have an alternative mutation that similarly activates the JAK- STAT pathway, such as mutations in the exon 12 of the JAK2 gene. In aggregate, these described mutations are present in 98% of PV and not in secondary forms of erythrocytosis. The current WHO diagnostic criteria for PV have been updated with proposed criteria (Figure 1) that establish the diagnosis of PV by both the presence of clear erythrocytosis or increased red cell mass and the presence of a known PV molecular lesion (JAK2V617F or JAK2 exon 12 mutation). 10 If both the latter features are present, a diagnosis of PV is highly likely and can be confirmed by the presence of one of the minor criteria, such as bone marrow biopsy consistent with PV (hypercellularity and panmyelosis with prominent trilineage proliferation). In the rare circumstance of patients with PV lacking the known PV molecular lesion, the diagnosis can still be established if two of the minor criteria are reached. The updated WHO criteria have the practical advantage of greatly simplifying the diagnosis of those with erythrocytosis who are JAK2V167F- positive who are highly likely to have PV. Figure 1. Current 9 and proposed 10 World Health Organization diagnostic criteria for the myeloproliferative disorders of polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). *Vardiman JW et al. WHO histological classification of chronic myeloproliferative diseases. In: Jaffe ES, Harris NL, Vardiman JW, eds. World Health Organization Classification of Tumors: Tumours of the Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer (IARC) Press; #Diagnostic bone marrow changes for each diagnosis discussed in text. Essential thrombocythemia The negative predictive value of a wildtype JAK2V617F mutation is significantly more limited in ET, given that only about 50% of afflicted individuals express the mutation; 2,3,5 however, its presence is diagnostically helpful. In the revised WHO criteria for ET 10 (Figure 2), sustained unexplained thrombocytosis has been lowered from /L to any sustained value greater than normal (> /L) given the fact that many patients with ET, even with thrombosis, can present with platelet counts between 450 and /L. Second, if the JAK2V617F is present (or another marker of clonality by karyotype is met), the burden of clinical investigations to exclude secondary 356 American Society of Hematology
3 Figure 2. Current available therapies for the myeloproliferative disorders and their overall impact upon the disease. causes is diminished. The need to exclude other potential myeloid disorders, and bone marrow morphology (proliferation of the megakaryocytic lineage) with increased numbers of enlarged, mature megakaryocytes (without significant increases in other myeloid lineages) consistent with ET remains largely unchanged. Primary myelofibrosis PMF has been known by a wide range of synonyms, including chronic idiopathic myelofibrosis, agnogenic myeloid metaplasia, and myelofibrosis with myeloid metaplasia. Given that the disorder is neither idiopathic nor always accompanied by myeloid metaplasia, the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT; an international ad hoc collaborative group of more than 40 dedicated myelofibrosis and MPD experts) reached the consensus that PMF would be the most accurate and appropriate diagnostic term. 11 PMF is the term used for patients who present with de novo disease; patients who progress to a myelofibrotic stage from previous PV or ET are designated post-pv myelofibrosis (post-pv MF) and post- ET myelofibrosis (post-et MF), respectively. 11 The proposed new WHO criteria 10 attempt to bridge the spectrum across the phenotypic variability in the disorder by requiring that three main features must be present to diagnose PMF (Figure 1): 1) Bone marrow histologic changes consistent with the disorder, specifically the presence of megakaryocyte proliferation and atypia (small to large megakaryocytes with an aberrant nuclear cytoplasmic ratio and hyperchromatic, bulbous, or irregularly folded nuclei and dense clustering), which are usually accompanied by either reticulin and/or collagen fibrosis. However, in the absence of significant reticulin fibrosis, the megakaryocyte changes must be accompanied by an increased bone marrow cellularity characterized by granulocytic proliferation and often decreased erythropoiesis (this substitutes for the previous pre-fibrotic/cellular-phase disease). 2) Absence of criteria suggesting an alternative myeloid disorder. 3) Either a marker of clonality (such as JAK2V617F or c-mplw515l/k) or, if such a clonal marker is absent, no evidence of the fibrosis being related to an inflammatory or reactive state. Two out of four minor criteria are required to secure the diagnosis of PMF, including peripheral blood manifestations (anemia, leukoerythroblastosis, or increased lactate dehydrogenase) or splenomegaly (presumably from extramedullary hematopoiesis). Although the updated WHO diagnostic criteria should provide a simplified and clearer diagnostic algorithm (especially in those with a clear MPD clonal molecular marker), further evolution of diagnostic criteria can be anticipated in the future. Indeed, as the biological underpinnings of the MPDs become further elucidated, we may be able to simplify these criteria further with less reliance on subjective clinical features or histologic interpretation of marrow trephines. Does Improved Pathogenetic Understanding Equal Better Therapies for MPDs? Current therapy of MPDs: an overview The natural history of MPDs has a variable period of risk of vascular events and a long-term risk of transformation to either an overt myelofibrotic phase or death. Current available therapies have rarely been able to impact this natural history beyond palliating symptoms or decreasing the risk of vascular events (Figure 2). Given these challenges, how should patients with MPD be optimally managed? Currently, incorporation of the modest numbers of randomized clinical trials, larger numbers of nonrandomized phase 2 trials, and clinical judgment all need to be considered in developing a therapeutic algorithm for the MPDs (Figure 3). Therapeutic algorithms for the MPDs will continue to evolve as therapeutic modalities improve and are vetted by appropriate clinical trials. After the appropriate diagnosis of an MPD is established, or sometimes even suspected, patients need to be stabilized for immediate coagulopathies from severe erythrocytosis, thrombocytosis, or concurrent or pre-existing thrombotic events. Management decisions will then partially flow from the clinician s estimation of overall disease prognosis and the separate estimation of the risk of vascular events (Figure 3). Patients with ET and PV are Hematology
4 Figure 3. Therapeutic algorithm: How I treat the MPDs for the chronic myeloproliferative disorders of polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). defined as high-risk when they have either had a prior vascular event or are older than 60 years of age; low-risk patients meet neither of these criteria (and have platelet counts < /L). Intermediate-risk ET and PV lack these prior features but have cardiovascular risk factors. Newly identified potential vascular risk factors include leukocytosis at diagnosis (at least in PV; > /L 12 ) or high JAK2V617F mutation allele burden. 13 Whether these new factors should be included in modeling MPD vascular risk is not yet known, and requires further study. Overall prognostic models for survival are best established in PMF, in which the Lille criteria 14 (based on anemia or marked leukocytosis/leukopenia) and subsequent complete blood count score (the Lille criteria with further stratification if thrombocytopenia present) have been the most clinically relevant. 15 Short-term plan The immediate therapeutic concerns for patients with MPD at presentation are both an adequate prophylaxis against vascular events and palliation when possible of MPD symptomatology. Available therapies for both ET and PV, up this juncture, have only been successful in decreasing the risks of thrombotic or hemorrhagic (i.e., vascular) events. Management of patients with PV includes control of erythrocytosis (by phlebotomy) and, when no contraindication exists, the use of low-dose aspirin as validated by the ECLAP study (European Collaborative Low-Dose Aspirin Trial). 16 The degree to which a patient needs to be phlebotomized has been questioned, with traditional dogma suggesting a goal hematocrit of less than 42% for women and 45% for men. Recent retrospective analysis of vascular events of patients on the ECLAP trial has suggested that modestly higher targets (perhaps up to hematocrits of 55%) may not increase the risk of vascular events. 17 Whether hematocrit goals should be changed for PV is a question that should be addressed by appropriately designed trials. What about myelosuppressive therapy for managing the MPDs? Hydroxyurea was shown in a randomized fashion to aid in the prevention of thrombotic events in patients with high-risk ET. 18 The UK MRC (United Kingdom Medical Research Council) PT-1 (primary thrombocythemia-1) trial compared in a randomized fashion hydroxyurea and anagrelide (both along with low-dose aspi- 358 American Society of Hematology
5 rin) for patients with ET and found hydroxyurea plus aspirin to be superior in regards to preventing arterial events, hemorrhage, and transformation to post-et MF. 19 Similar randomized data for the use of hydroxyurea or other myelosuppressive agent in high-risk PV do not yet exist; however, in the absence of such data, it remains the most commonly used agent in practice. 20 Therefore, hydroxyurea is the standard front-line therapy for high-risk patients with ET and PV (based on clinical experience) who require platelet-lowering therapy. Although concerns linger as to whether hydroxyurea accelerates an MPD towards leukemic transformation, this has never been proven when hydroxyurea is used as a single agent. 21 The use of pegylated IFN-α2A has shown intriguing activity, and potentially improved tolerability, over traditional IFN, especially for PV (Table 1). 22 How IFN compares with hydroxyurea for control of vascular events has not yet been studied in a randomized fashion. Palliating symptoms in patients with MPD can include therapies for pruritus (antihistamines and selective serotonin reuptake inhibitors), erythromelalgia (aspirin), and fatigue (no clear therapy has been proven efficacious, but exercise may help as it has in other malignancies 23 ) (Figures 2 and 3). Cytopenias have improved in subsets of patients with erythropoietin supplementation, 24 androgens, 25 and/or corticosteroids. Similarly, the use of nonspecific myelosuppressive regimens such as oral hydroxyurea 26 and cladribine 27 have all been reported to provide palliative reduction in painful splenomegaly. Long-term therapeutic plan Currently, no therapy has been shown to be curative, to alter natural history, or to prolong survival in patients with MPD, with the exception of allogeneic stem cell transplantation. The long-term therapeutic plan for patients with MPD, and particularly those with PMF (and post-et/pv MF), can be divided into observation, proceeding directly to an allogeneic stem cell transplant, and enrollment in an appropriate clinical trial. Observation as a medical plan implies continued vigilance and therapy for prevention of vascular events and appropriate therapy for palliation of MPD symptoms. Observation is most appropriate for those patients with low-risk PMF, and controlled ET and PV. In addition, observation requires continued vigilance of the patient s disease status for disease progression to a point where a clinical trial would be appropriate or a stem cell transplantation would be considered. The choice and role of allogeneic stem cell transplantation for patients with MPD remains an evolving question. Among the MPDs, allogeneic stem cell transplantation is most attractive for high-risk PMF, given that this MPD is the most likely to decrease survival among those Table 1. Investigational medical therapies for the BCR-ABL negative myeloproliferative disorders. Disease Agent Class/type of drug Route Phase Reference Immunomodulatory agents PV/ET Pegylated interferon-2a Immunomodulatory agent SQ 2 22 PMF/post-ET/PV MF Lenalidomide + prednisone Immunomodulatory agent Oral 2 43 PMF/post-ET/PV MF CC-4047 ± prednisone Immunomodulatory agent Oral 2 Ongoing Targeting the stromal reaction PMF/post-ET/PV MF GC-1008 Pan-specific human IV 2 44 anti TGF-β antibody PMF/post-ET/PV MF Bevacizumab Anti-VEGF monoclonal antibody IV 2 45 DNA hypomethylating agents PMF/post-ET/PV MF Azacitidine Hypomethylating agent SQ 2 Ongoing PMF/post-ET/PV MF Decitabine Hypomethylating agent IV 2 Ongoing Targeting apoptosis agents PMF/post-ET/PV MF Bortezomib Proteasome inhibitor IV 2 46 Kinase inhibitory agents PMF/post-ET/PV MF Dasatinib Kinase inhibitor Oral 2 47 JAK2 inhibitors in development PMF/post-ET/PV MF (at first) TG JAK2 inhibitor Oral 1/2 37 PMF/post-ET/PV MF (at first) Go6976 FLT3-JAK2 inhibitor Unknown Preclinical 38 PMF/post-ET/PV MF (at first) Erlotinib JAK2 inhibitor Oral 1/2 39 PMF/post-ET/PV MF (at first) MK 0457 Aurora kinase inhibitor IV 1/2 40 PMF/post-ET/PV MF (at first) CEP-701 FLT3-JAK2 inhibitor Oral 1/2 41 Abbreviations: PV, polycythemia vera; ET, essential thrombocythemia; PMF, primary myelofibrosis; MF, myelofibrosis; IV, intravenous; SQ, subcutaneous; TGF, tumor growth factor; VEGF, vascular endothelial growth factor Hematology
6 afflicted. Recent reports describe a 58% 3-year survival in a group of 56 patients with PMF (and post-et/pv MF) (age 10-66), with a 32% nonrelapse mortality rate. 28 The significant toxicity of full allogeneic transplantation in PMF led to exploration of the use of reduced-intensity conditioning trials. 29 The latter trials have been encouraging in terms of decreased nonrelapse mortality and increased age range of those who underwent transplantation successfully. However, allogeneic transplant still carries a significant risk of graft-versus-host disease (at least 33%), and the exact role and benefit depends on the long-term prognosis of the patient. The significant risks of any of the stem cell transplantation procedures make it difficult to justify this therapy for ET and PV given the overall good prognosis of these patients. Clinical Trials for the MPDs: Current and Future Immunomodulation and targeting the stroma The group of immunomodulatory cytokine inhibitory and anti-angiogenic agents collectively known as IMIDs have shown promise in the MPDs, and most specifically in PMF and post-et/pv MF. Initial pilot studies with thalidomide in PMF were dose escalating in nature, beginning at doses of 100 mg/day. 30 Subsequent low-dose (50 mg/day) thalidomide with a prednisone taper 31 resulted in significant responses for anemia (67%), thrombocytopenia (75%), and splenomegaly (33%) without demonstrating, however, any definitive improvement in marrow or karyotypic abnormalities. Subsequently, lenalidomide (a second-generation, more potent cytokine-inhibitory IMID) was been evaluated in 68 patients with symptomatic PMF, with overall response rates of 22% for anemia, 33% for splenomegaly, and 50% for thrombocytopenia; 32 however, improved marrow histology is seen in small number of the responders (4 of the 68 enrolled). Mirroring the activity of lenalidomide in del(5q) myelodysplastic syndrome, the small number of patients with PMF with an abnormality of chromosome 5 have the potential for significant response. 33 Given the promising results obtained with lenalidomide, a randomized, placebo-controlled, international clinical study to determine the activity of pomalidomide (20,000-fold more potent than thalidomide in inhibiting TNF-α) with or without a prednisone taper in PMF and post-et/pv MF is currently under way. Multiple other attempts at targeting the bone marrow stromal reaction in PMF (post-et/pv MF), angiogenesis or DNA hypermethylation are underway in a series of ongoing trials (Table 1). The next generation of targeted therapy for PMF will move beyond agents targeting the stromal reaction, or cytokines, to agents aimed at the aberrant clone and constitutively active proliferative stimuli. Tyrosine kinase inhibitors have been of great benefit to patients when a molecular target exists (e.g., imatinib mesylate and chronic myeloid leukemia). Attempts to use current tyrosine kinase inhibitors in MPDs have been modest, 34 while other studies in PMF have shown activity with thrombocytopenia 35 but potentially with severe toxicity, 36 and trials investigating second generation agents are ongoing (Table 1). JAK2 inhibitors Although the currently identified molecular defects in patients with MPD do not yet fully explain many issues of MPD pathogenesis, they provide an exciting and hopefully more fruitful therapeutic target. There have already been multiple reports of agents in development that have demonstrated the ability to inhibit the aberrant JAK2V617F, along with the wild-type JAK2, such as TG101209, 37 Go6976, 38 erlotinib, 39 MK0457, 40 and CEP Intriguingly, in primary cells from patients with wild-type JAK2 who have the c-mplw515l/k, growth inhibition can similarly be accomplished by JAK2 inhibitors such as TG These latter observations suggest the possibility that even in patients with JAK2 wild-type MPD, a growth dependence on the JAK-STAT pathway may exist, and agents targeting this pathway may be active regardless of the JAK2 mutation status. This hypothesis is further supported by the continual discovery of aberrations in this pathway, as in exon 12 of the JAK2 gene in patients with JAK2V617F-negative PV. 8 What effects can we expect to observe from the inhibition of JAK2 (no medication is likely to strictly inhibit the JAK2V617F)? Will inhibition of the JAK-STAT pathway decrease myeloproliferation (Figure 1)? Will JAK-STAT inhibition decrease the development of thrombohemorrhagic events, given the multifactorial nature of their origin? What about the major therapeutic endpoints desired by clinicians and patients, namely delaying or preventing disease progression, or increasing survival? Uncertainty exists as to whether the inhibition of JAK2 will accomplish these goals, since the exact role of the JAK2V617F mutation in disease progression or development of blast-phase PMF remains unclear. The observation that patients with JAK2-mutant MPD have the potential to develop acute leukemia from a JAK2 wild-type clone 42 questions the role of this mutation in disease progression. Therefore, what effect JAK2 inhibition will have on disease progression is quite uncertain and will require close, longterm monitoring of patients taking JAK2 inhibitors to be certain no adverse impact arises from the use of these agents. Finally, if beneficial, will the JAK2 inhibitors lead to the cure? Although unlikely at this juncture, efficacy in shortand long-term control of the disease would be greatly welcomed by physician and patient alike. Correspondence Ruben A. Mesa, MD, Mayo Clinic, 200 First Street, SW, Rochester, MN 55902; phone (507) ; fax (507) ; mesa.ruben@mayo.edu References 1. Damashek W. Some speculations on the myeloproliferative syndrome. Blood. 1951;6: American Society of Hematology
7 2. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365: Kralovics R, Passamonti F, Buser AS, et al. A gain-offunction mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352: James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434: Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myelofibrosis with myeloid metaplasia. Cancer Cell. 2005;7: Tefferi A, Gilliland DG. Oncogenes in myeloproliferative disorders. Cell Cycle. 2007;6: Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108: Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356: Vardiman JW, Brunning RD, Harris NL. WHO histological classification of chronic myeloproliferative diseases. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumors: Tumours of the Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer (IARC) Press; 2001: Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110: Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-pv MF), post essential thrombocythemia myelofibrosis (post-et MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007;31: Landolfi R, Di Gennaro L, Barbui T, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 2007;109: Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110: Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88: Dingli D, Schwager SM, Mesa RA, Li CY, Tefferi A. Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system. Cancer. 2006;106: Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350: Di Nisio M, Barbui T, Di Gennaro L, et al. The haematocrit and platelet target in polycythemia vera. Br J Haematol. 2007;136: Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332: Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353: Finazzi G, Barbui T. Risk-adapted therapy in essential thrombocythemia and polycythemia vera. Blood Rev. 2005;19: Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005;105: Kiladjian JJ, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood. 2006;108: Dimeo F, Schwartz S, Fietz T, Wanjura T, Boning D, Thiel E. Effects of endurance training on the physical performance of patients with hematological malignancies during chemotherapy. Support Care Cancer. 2003;11: Cervantes F, Alvarez-Larran A, Hernandez-Boluda JC, Sureda A, Torrebadell M, Montserrat E. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol. 2004;127: Cervantes F, Hernandez-Boluda JC, Alvarez A, Nadal E, Montserrat E. Danazol treatment of idiopathic myelofibrosis with severe anemia. Haematologica. 2000;85: Lofvenberg E, Wahlin A, Roos G, Ost A. Reversal of myelofibrosis by hydroxyurea. Eur J Haematol. 1990;44: Faoro LN, Tefferi A, Mesa RA. Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia. Eur J Haematol. 2005;74: Deeg HJ, Gooley TA, Flowers ME, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood. 2003;102: Rondelli D, Barosi G, Bacigalupo A, et al. Allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in intermediate or high risk patients with myelofibrosis with myeloid metaplasia. Blood. 2005;105: Barosi G, Grossi A, Comotti B, Musto P, Gamba G, Marchetti M. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 2001;114: Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood. 2003;101: Tefferi A, Cortes J, Verstovsek S, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006;108: Tefferi A, Lasho TL, Mesa RA, Pardanani A, Ketterling RP, Hanson CA. Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. Leukemia. 2007;21: Silver RT. Imatinib mesylate (Gleevec TM ) reduces phlebotomy requirements in polycythemia vera. Leukemia. 2003;17: Cortes J, Giles F, O Brien S, et al. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer. 2003;97: Tefferi A, Mesa RA, Gray LA, et al. Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. Blood. 2002;99: Pardanani A, Hood J, Lasho T, et al. TG101209, a selective JAK2 kinase inhibitor, suppresses endogenous and cytokine-supported colony formation from hematopoietic progenitors carrying JAK2V617F or MPLW515K/L mutations [abstract]. Blood. 2006;108:2680a. 38. Grandage VL, Everington T, Linch DC, Khwaja A. Go6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells. Br J Haematol. 2006;135: Hematology
8 39. Li Z, Xu M, Xing S, et al. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem. 2006;282: Giles F, Freedman SJ, Xiao A, et al. MK-0457, a novel multikinase inhibitor, has activity in refractory AML, including transformed JAK2 positive myeloproliferative disease (MPD), and in Philadelphia-positive ALL [abstract]. Blood. 2006;108:1967a. 41. Dobrzanski P, Hexner E, Serdikoff C, et al. CEP-701 Is a JAK2 inhibitor which attenuates JAK2/STAT5 signaling pathway and the proliferation of primary cells from patients with myeloproliferative disorders [abstract]. Blood. 2006;108:3594a. 42. Theocharides A, Boissinot M, Garand R, et al. Myeloid blasts in transformed JAK2-V617F positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation [abstract]. Blood. 2006;108:375a. 43. Tefferi A, Cortes J, Verstovsek S, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006;108: Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov. 2004;3: Cardones AR, Banez LL. VEGF inhibitors in cancer therapy. Curr Pharm Des. 2006;12: Wagner-Ballon O, Gastinne, T, Tulliez, M, et al. Proteasome inhibitor bortezomib can inhibit bone marrow fibrosis development in a murine model of myelofibrosis [abstract]. Blood. 2005;106:abstract # Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2- chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5- carboxamide (BMS ), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47: American Society of Hematology
Primary myelofibrosis (PMF) is a hematologic malignancy
Brief Report Mature Survival Data for 176 Patients Younger Than With Primary Myelofibrosis Diagnosed Between 1976 and 5: Evidence for Survival Gains in Recent Rakhee Vaidya, MBBS; Sergio Siragusa, MD;
More informationWHO Update to Myeloproliferative Neoplasms
WHO Update to Myeloproliferative Neoplasms Archana M Agarwal, MD, Associate Professor of Pathology University of Utah Department of Pathology/ARUP Laboratories Myeloproliferative Neoplasms The categories
More informationWelcome to Master Class for Oncologists. Session 3: 9:15 AM - 10:00 AM
Welcome to Master Class for Oncologists Session 3: 9:15 AM - 10:00 AM Miami, FL December 18, 2009 Myeloproliferative Neoplasms: Bringing Order to Complexity and Achieving Optimal Outcomes Speaker: Andrew
More informationTechnical Bulletin No. 100
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 100 August 2, 2012 JAK2 AND MPL 515 MUTATIONAL ANALYSIS Contact: Dr. Jeffrey Wisotzkey, 717-851-1422 Technical Director, CPAL Jill A.
More informationTransplants for MPD and MDS
Transplants for MPD and MDS The question is really who to transplant, with what and when. Focus on myelofibrosis Jeff Szer Royal Melbourne Hospital Myelodysplasia Little needs to be said Despite new therapies
More informationLondon Cancer. Myelofibrosis guidelines. August Review August Version v1.0. Page 1 of 12
London Cancer Myelofibrosis guidelines August 2013 Review August 2013 Version v1.0 Page 1 of 12 CONTENTS 1. DIAGNOSIS... 3 1a. BCSH (2012)... 3 1b. WHO (2009) diagnostic criteria for PMF:... 4 2. MOLECULAR
More informationMYELOPROLIFERATIVE NEOPLASMS
9 : 2 MYELOPROLIFERATIVE NEOPLASMS Introduction William Dameshek in 1951 introduced the term Myeloproliferative disorders (MPD). This included polycythemia vera (PV), essential thrombocythemia (ET), primary
More informationNew Therapies for MPNs
Pomalidomide and IMIDS in Myelofibrosis New Therapies for MPNs Fourth International Workshop on CML and MPN Natchez Louisiana Ruben A. Mesa, MD Professor of Medicine Mayo Clinic College of Medicine Director
More informationEmerging diagnostic and risk stratification criteria
PV STATE OF MIND Polycythemia vera: Emerging diagnostic and risk stratification criteria Rami S. Komrokji, MD Moffitt Cancer Center, Tampa, Florida Disclosure These slides were developed by Incyte Corporation
More informationORIGINAL ARTICLE. A Tefferi 1, TL Lasho 1, J Huang 1, C Finke 1, RA Mesa 1,CYLi 2,WWu 3, CA Hanson 2 and A Pardanani 1
(28) 22, 756 76 & 28 Nature Publishing Group All rights reserved 887-6924/8 $3. www.nature.com/leu ORIGINAL ARTICLE, compared to either a higher allele burden or unmutated status, is associated with inferior
More informationBone marrow histopathology in Ph - CMPDs. - the new WHO classification - Juergen Thiele Cologne, Germany
Bone marrow histopathology in Ph - CMPDs - the new WHO classification - Juergen Thiele Cologne, Germany Current issues in MPNs concerning morphology 1.Prodromal stages of disease 2.Impact of histopathology
More informationOpportunities for Optimal Testing in the Myeloproliferative Neoplasms. Curtis A. Hanson, MD
Opportunities for Optimal Testing in the Myeloproliferative Neoplasms Curtis A. Hanson, MD 2013 MFMER slide-1 DISCLOSURES: Relevant Financial Relationship(s) None Off Label Usage None 2013 MFMER slide-2
More informationDisclosure BCR/ABL1-Negative Classical Myeloproliferative Neoplasms
Disclosure BCR/ABL1-Negative Classical Myeloproliferative Neoplasms Sonam Prakash declares affiliation with Incyte Corporation: Advisor for Hematopathology Publications Steering Committee Sonam Prakash,
More informationPolycythemia Vera and Essential Thombocythemia A Single Institution Experience
INDIAN JOURNAL OF MEDICAL & PAEDIATRIC ONCOLOGY Vol. 29 No 4, 2008 7 Original Article-I Polycythemia Vera and Essential Thombocythemia A Single Institution Experience CECIL ROSS, NAVYA, VANAMALA AND KARUNA
More informationMyelodysplastic Syndromes Myeloproliferative Disorders
Myelodysplastic Syndromes Myeloproliferative Disorders Myelodysplastic Syndromes characterized by maturation defects that are associated with ineffective hematopoiesis and a high risk of transformation
More informationCLINICAL POLICY DEPARTMENT: Medical Management DOCUMENT NAME: JakafiTM REFERENCE NUMBER: NH.PHAR.98
PAGE: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationJAK inhibitors in Phmyeloproliferative
Disclosures for A Pardanani Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board TargeGen, Cytopia/YM BioSciences, PharmaMar None None None None None Presentation
More informationDisclosures for Ayalew Tefferi
Disclosures for Ayalew Tefferi Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Janssen, Geron, Celgene, Sanofi-Aventis, Gilead Sciences, Incyte
More informationMyelodysplastic syndrome (MDS) & Myeloproliferative neoplasms
Myelodysplastic syndrome (MDS) & Myeloproliferative neoplasms Myelodysplastic syndrome (MDS) A multipotent stem cell that can differentiate into any of the myeloid lineage cells (RBCs, granulocytes, megakaryocytes)
More informationClassification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2V617F Era
Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2V617F Era Ayalew Tefferi JAK2V617F, a somatic gain-of-function mutation involving the JAK2 tyrosine kinase gene, occurs
More informationHeme 9 Myeloid neoplasms
Heme 9 Myeloid neoplasms The minimum number of blasts to diagnose acute myeloid leukemia is 5% 10% 20% 50% 80% AML with the best prognosis is AML with recurrent cytogenetic abnormality AML with myelodysplasia
More informationManaging ET in Tiziano Barbui MD
Managing ET in 2019 Tiziano Barbui MD (tbarbui@asst-pg23.it) Hematology and Foundation for Clinical Research, Hospital Papa Giovanni XXIII Bergamo, Italy Managing ET in 2019 Establish diagnosis Risk Stratification
More informationImatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders
REVIEW Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders Ruben A Mesa Division of Hematology, Mayo Clinic, Rochester, MN, USA Abstract: The chronic
More informationPractice Patterns in the Diagnosis and Treatment of Polycythemia Vera in the Post JAK2 V617F Discovery Era
1238 Original Research Practice Patterns in the Diagnosis and Treatment of Polycythemia Vera in the Post JAK2 V617F Discovery Era Elizabeth M. Kander, MD a ; Alison R. Moliterno, MD b ; Alfred Rademaker,
More informationDisclosures. Myeloproliferative Neoplasms: A Case-Based Approach. Objectives. Myeloproliferative Neoplasms. Myeloproliferative Neoplasms
Myeloproliferative Neoplasms: A Case-Based Approach Disclosures No conflicts of interests regarding the topic being presented Adam M. Miller, MD PGY-4 Resident Physician Department of Pathology and Laboratory
More information74y old Female with chronic elevation of Platelet count. August 18, 2005 Faizi Ali, MD Hematopathology Fellow
74y old Female with chronic elevation of Platelet count August 18, 2005 Faizi Ali, MD Hematopathology Fellow Clinical History Patient is a 74y old otherwise healthy Caucasian female with no major complaint
More informationMyeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas. James J. Stark, MD, FACP
Myeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS
More informationHydroxyurea: the comparator in studies with new anti-jak2 inhibitors
Hematology Meeting Reports 2009;3(3):108 114 SESSION VIII xg. Finazzi T. Barbui 1 x Divisione di Ematologia e 1 Fondazione per la Ricerca Ospedali Riuniti di Bergamo, Italy Hydroxyurea: the comparator
More informationMyeloproliferative Disorders - D Savage - 9 Jan 2002
Disease Usual phenotype acute leukemia precursor chronic leukemia low grade lymphoma myeloma differentiated Total WBC > 60 leukemoid reaction acute leukemia Blast Pro Myel Meta Band Seg Lymph 0 0 0 2
More informationGreater Manchester and Cheshire Cancer Network
Greater Manchester and Cheshire Cancer Network Guidelines for the diagnosis and treatment of primary myelofibrosis, post-essential thrombocythaemia myelofibrosis and post-polycythaemia myelofibrosis Tim
More informationJAK2 Inhibitors for Myeloproliferative Diseases
JAK2 Inhibitors for Myeloproliferative Diseases Srdan (Serge) Verstovsek M.D., Ph.D. Associate Professor Department of Leukemia University of Texas MD Anderson Cancer Center Houston, Texas, USA Myeloproliferative
More informationMyeloproliferative Neoplasms and Treatment Overview
Myeloproliferative Neoplasms and Treatment Overview George Nesr Clinical Research Fellow in Haematology Haematology Department Imperial College Healthcare NHS Trust Overview Historical Background Pathogenesis
More informationDisclosures for Ayalew Tefferi
Disclosures for Ayalew Tefferi Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Janssen, Geron, Celgene, Sanofi-Aventis, Gilead Sciences, Incyte
More informationPolycthemia Vera (Rubra)
Polycthemia Vera (Rubra) Polycthemia Vera (Rubra) Increased red cells Clonal Myeloid lineages also increased 2-13 cases per million Mean age: 60 years Sites of Involvement Bone marrow Peripheral blood
More informationWhat is next: Emerging JAK2 inhibitor combination studies. Alessandro M. Vannucchi. Section of Hematology, University of Florence, Italy
ymposium JAK2 Inhibition in Myelofibrosis: What Can We Expect in the Clinic? 4 5 May 2012 Lisbon, Portugal What is next: Emerging JAK2 inhibitor combination studies Alessandro M. Vannucchi ection of Hematology,
More informationChronic Myeloproliferative Disorders
1 Chronic Myeloproliferative Disorders 15th 9 April2015 Polycythemia vera Essential thrombocythemia Idiopathic primary myelofibrosis 2 Learning objectives To appreciate types of polycythaemia (erythrocytosis)
More informationTemplate for Reporting Results of Biomarker Testing for Myeloproliferative Neoplasms
Template for Reporting Results of Biomarker Testing for Myeloproliferative Neoplasms Version: MPNBiomarkers 1.0.0.2 Protocol Posting Date: June 2017 This biomarker template is NOT required for accreditation
More informationUnderstanding how Jakafi (ruxolitinib) inhibits* overactive JAK pathway signaling
Understanding how Jakafi (ruxolitinib) inhibits* overactive JAK pathway signaling * Jakafi, a kinase inhibitor, inhibits and (Janus-associated kinases 1 and 2), which mediate the signaling of cytokines
More informationMPN What's new in the morphological classification, grading of fibrosis and the impact of novel drugs
MPN What's new in the morphological classification, grading of fibrosis and the impact of novel drugs Hans Michael Kvasnicka University of Frankfurt, Germany hans-michael.kvasnicka@kgu.de Disclosure of
More informationMyeloid neoplasms. Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories:
Myeloid neoplasms Note: Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories: 1. AML : Acute myeloid leukemia(stem cell with myeloid
More informationChronic Idiopathic Myelofibrosis (CIMF)
Chronic Idiopathic Myelofibrosis (CIMF) CIMF Synonyms Agnogenic myeloid metaplasia Myelosclerosis with myeloid metaplasia Chronic granulocytic-megakaryocytic myelosis CIMF Megakaryocytic proliferation
More informationPolycythemia Vera and other Myeloproliferative Neoplasms. A.Mousavi
Polycythemia Vera and other Myeloproliferative Neoplasms A.Mousavi Chronic MPNs Multipotent hematopoietic progenitor cell is origin. Overproduction of one or more formed element of blood cells without
More informationMPNs: JAK2 inhibitors & beyond. Mohamed Abdelmooti (MD) NCI, Cairo University, Egypt
MPNs: JAK2 inhibitors & beyond Mohamed Abdelmooti (MD) NCI, Cairo University, Egypt Myeloproliferative Neoplasms (MPNs) AGENDA: 1. Molecular biology 2. New WHO diagnostic criteria. 3. Risk stratification
More informationThe Internists Approach to Polycythemia and Implications of Uncontrolled Disease
The Internists Approach to Polycythemia and Implications of Uncontrolled Disease Mary Jo K. Voelpel, DO, FACOI, MA, CS Associate Clinical Professor MSU-COM Disclosures NONE Overview 1. Objectives 2. Case
More informationGuidelines for diagnosis and management of adult myeloproliferative neoplasms (PV, ET, PMF and HES)
Guidelines for diagnosis and management of adult myeloproliferative neoplasms (PV, ET, PMF and HES) Author: Dr N Butt, Consultant Haematologist On behalf of the Haematology CNG Written: July 2010 Reviewed:
More informationMyeloproliferative Disorders in the Elderly: Clinical Presentation and Role of Bone Marrow Examination
Myeloproliferative Disorders in the Elderly: Clinical Presentation and Role of Bone Marrow Examination Arati V. Rao, M.D. Division of Medical Oncology and Geriatrics Duke University Medical Center Durham
More informationStifel Nicolaus 2013 Healthcare Conference. John Scarlett, M.D. Chief Executive Officer September 11, 2013
Stifel Nicolaus 2013 Healthcare Conference John Scarlett, M.D. Chief Executive Officer September 11, 2013 1 forward-looking statements Except for the historical information contained herein, this presentation
More informationPresenter Disclosure Information
Welcome to Master Class for Oncologists Session 3: 2: PM 3:3 PM Pasadena, CA May 1, 21 Myeloproliferative Neoplasms 21 Speaker: Ayalew Tefferi Mayo Clinic, Rochester, MN Presenter Disclosure Information
More informationThe treatment of polycythaemia vera: an update in the JAK2 era
Intern Emerg Med (2007) 2:13 18 DOI 10.1007/s11739-007-0003-4 IM REVIEW G. Finazzi T. Barbui The treatment of polycythaemia vera: an update in the JAK2 era Received: 31 August 2006 / Accepted in original
More informationHow to monitor MPN patients
How to monitor MPN patients MPN carries significant burden and risk Transformation to MF or AML 1 Neurological complications 2 MPN-associated general symptoms (eg, pruritus, fatigue) 3 Microvascular symptoms
More informationMyelofibrosis a Reference Guide for Journalists
Myelofibrosis a Reference Guide for Journalists What Is Myelofibrosis? Myelofibrosis is an uncommon blood cancer characterized by bone marrow scarring (fibrosis), enlarged spleen (splenomegaly), potential
More informationHow I Treat Myelofibrosis. Adam Mead, MD, PhD University of Oxford Oxford, United Kingdom
How I Treat Myelofibrosis Adam Mead, MD, PhD University of Oxford Oxford, United Kingdom Primary Myelofibrosis Archiv Fur Pathol. 1879;78:475-96. 2 cases of leukemia with peculiar blood and marrow findings
More informationPractical Considerations in the Treatment Myeloproliferative Neoplasms: Prognostication and Current Treatment Indy Hematology
Practical Considerations in the Treatment Myeloproliferative Neoplasms: Prognostication and Current Treatment Indy Hematology Angela Fleischman MD PhD UC Irvine March 9, 2019 Disclosures: Angela Fleischman
More information[COMPREHENSIVE GENETIC ASSAY PANEL ON
2014 SN GENELAB AND RESEARCH CENTER DR. SALIL VANIAWALA, PH.D [COMPREHENSIVE GENETIC ASSAY PANEL ON MYELOPROLIFERATIVE NEOPLASMS] SN Genelab presents one of the most comprehensive genetic assay panel for
More informationPolycythemia vera: Emerging diagnostic and risk stratification criteria
This article, sponsed by Incyte Cpation, is based on a paid interview with Rami S. Komrokji, MD, of Moffitt Cancer Center, Tampa, Flida, conducted on May 4, 2015. Polycythemia vera: Emerging diagnostic
More informationThe 2008 World Health Organization Classification System for Myeloproliferative Neoplasms
Review Article The 2008 World Health Organization Classification System for Myeloproliferative Neoplasms Order Out of Chaos Ayalew Tefferi, MD 1 ; Juergen Thiele, MD 2 ; and James W. Vardiman, MD 3 The
More informationBiologia molecolare delle malattie mieloproliferative croniche Ph1-negative tipiche
41 CONGRESSO NAZIONALE SIE Bologna 14-17 Ottobre 2007 Biologia molecolare delle malattie mieloproliferative croniche Ph1-negative tipiche Alessandro M. Vannucchi Dip.. di Ematologia, Università degli Studi
More informationThe prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia
Received: 3 February 2017 Revised: 13 February 2017 Accepted: 14 February 2017 DOI: 10.1002/ajh.24689 RESEARCH ARTICLE The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin
More informationPrognostic models in PV and ET
Prognostic models in PV and ET Francesco Passamonti Hematology, Varese, Italy Current risk stratification in PV and ET: statement from European LeukemiaNet consensus Age over 60 years Previuos thrombosis
More informationNew Advances in the Pathogenesis and Therapy of Essential Thrombocythemia
MYELOPROLIFERATIVE DISORDERS New Advances in the Pathogenesis and Therapy of Essential Thrombocythemia Ross L. Levine 1,2 and Mark Heaney 2 1 Human Oncology and Pathogenesis Program; 2 Leukemia Service,
More informationCharacterization of MPL-mutated myeloid neoplasms: a review of 224 MPL+ cases
Article Characterization of MPL-mutated myeloid neoplasms: a review of 224 MPL+ cases Keming Lin 1,*, Gang Xu 1, Jie-Gen Jiang 1, Mayuko Imai 1, Zhao Wu 1, Paris Petersen 1, Kim Janatpour 1, and Bashar
More informationJAK2 inhibitors in the treatment of myeloproliferative neoplasms: rationale and clinical data
JAK2 inhibitors in the treatment of myeloproliferative neoplasms: rationale and clinical data Clin. Invest. (2011) 1(12), 1681 1693 The seminal discovery of the high prevalence of the JAK2-V617F mutation
More informationRethinking Disease Definitions and Therapeutic Strategies in Essential Thrombocythemia and Polycythemia Vera
CLINICAL IMPACT OF TARGETED THERAPIES IN MYELOPROLIFERATIVE NEOPLASMS Rethinking Disease Definitions and Therapeutic Strategies in Essential Thrombocythemia and Polycythemia Vera Claire Harrison 1 1 Guy
More informationASH 2013 Analyst & Investor Event
ASH 2013 Analyst & Investor Event December 9, 2013 John A. Scarlett, MD President & CEO Forward-Looking Statements Except for the historical information contained herein, this presentation contains forward-looking
More informationMethylation status of SOCS1 and SOCS3 in BCR-ABL negative and. JAK2V617F negative chronic myeloproliferative disorders.
Methylation status of SOCS1 and SOCS3 in BCR-ABL negative and JAK2V617F negative chronic myeloproliferative disorders. To the Editor BCR-ABL negative Chronic Myeloproliferative Disorders (s) are a heterogeneous
More informationNew WHO Classification of Myeloproliferative Neoplasms
New WHO Classification of Myeloproliferative Neoplasms Hans Michael Kvasnicka Senckenberg Institute of Pathology, University of Frankfurt, Germany hans-michael.kvasnicka@kgu.de Principles and rationale
More informationMany smaller Canadian cancer centres or those
Literature-based followup recommendations Part 4: Myelodysplastic and myeloproliferative syndromes and management of iron overload in multiply-transfused oncology patients Malcolm Brigden, MD, FRCPC, FACP;
More informationWhat are myeloproliferative neoplasms??
Welcome to Master Class for Oncologists Session 3: 2:45 PM - 3:30 PM New York, NY October 24, 2008 Myeloproliferative Neoplasms Speaker: Ayalew Tefferi, MD Professor of Medicine, Mayo Clinic, Rochester,
More informationLeukemia and subsequent solid tumors among patients with myeloproliferative neoplasms
Leukemia and subsequent solid tumors among patients with myeloproliferative neoplasms Tiziano Barbui (tbarbui@asst-pg23.it Hematology and Research Foundation,Ospedale Papa Giovanni XXIII, Bergamo Italy
More informationDisclosures for Angela Fleischman
Disclosures for Angela Fleischman Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Sierra, Incyte None None None Incyte None Presentation includes
More informationPolycythemia Vera: From New, Modified Diagnostic Criteria to New Therapeutic Approaches
Polycythemia Vera: From New, Modified Diagnostic Criteria to New Therapeutic Approaches Margherita Maffioli, MD, Barbara Mora, MD, and Francesco Passamonti, MD Drs Maffioli and Mora are hematologists in
More informationCME Information: Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification, and management
AJH CME Information: Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification, and management Author: Ayalew Tefferi If you wish to receive credit for this activity,
More informationFocus on aggressive polycythemia vera
Focus on aggressive polycythemia vera Jerry L. Spivak, MD Professor of Medicine and Oncology Director, the Johns Hopkins Center for the Chronic Myeloproliferative Disorders Johns Hopkins University School
More informationSafety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
original article Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis Srdan Verstovsek, M.D., Ph.D., Hagop Kantarjian, M.D., Ruben A. Mesa, M.D., Animesh D. Pardanani, M.B., B.S.,
More informationMPL W515L K mutation
MPL W515L K mutation BCR-ABL genotyping The exact chromosomal defect in Philadelphia chromosome is a translocation. Parts of two chromosomes, 9 and 22, switch places. The result is a fusion gene, created
More informationRuxolitinib for myelofibrosis
EXPERIMENTAL AND THERAPEUTIC MEDICINE 5: 927-931, 2013 Ruxolitinib for myelofibrosis LIAN GU 1*, LI SU 2*, QING CHEN 1*, JUANJUAN XIE 1, GUANGLIANG WU 1, YAN YAN 1, BAOYUN LIANG 1, JINJING TAN 1 and NONG
More informationWhy do patients with polycythemia vera clot? Kinsey McCormick Hematology Fellows conference August 10, 2012
Why do patients with polycythemia vera clot? Kinsey McCormick Hematology Fellows conference August 10, 2012 Outline Case presentation Overview of PV Disease course Mechanisms of thrombosis Case Presentation
More informationDepartment of Hematology, Sakarya University Training and Research Hospital, Sakarya, Turkey.
Original Article Hematology Medical Journal of Islamic World Academy of Sciences doi: 10.5505/ias.2018.90093 2018;26(3): 59-64 Retrospective analysis of patients with chronic myeloproliferative neoplasms:
More informationPathology. #11 Acute Leukemias. Farah Banyhany. Dr. Sohaib Al- Khatib 23/2/16
35 Pathology #11 Acute Leukemias Farah Banyhany Dr. Sohaib Al- Khatib 23/2/16 1 Salam First of all, this tafreegh is NOT as long as you may think. If you just focus while studying this, everything will
More informationInternational Journal of Scientific & Engineering Research, Volume 8, Issue 12, December-2017 ISSN
ISSN 2229-5518 286 Overview of management strategies toward Thrombocythemia Mayada Amin Aljudaibi, Reem Ali Mohammed Alamoodi, Abrar Ali Mohammed Alamoodi, Samar Mohammed Hasan Al_Hashemi, Bashayer Sadagah
More informationBCR-ABL1 Negative Myeloproliferative Neoplasms: A Review of Molecular Biology, Diagnosis, and Treatment
Myeloproliferative Disorders BCR-ABL1 Negative Myeloproliferative Neoplasms: A Review of Molecular Biology, Diagnosis, and Treatment Erik Vakil, 1 Ayalew Tefferi 2 Abstract In 2008, the World Health Organization
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: October 15, 2018 Related Policies: None JAK2, MPL and CALR Testing for Myeloproliferative Neoplasms Description Somatic (acquired) genetic variants in JAK2, MPL,
More informationHENATOLYMPHOID SYSTEM THIRD YEAR MEDICAL STUDENTS- UNIVERSITY OF JORDAN AHMAD T. MANSOUR, MD. Part 4 MYELOID NEOPLASMS
HENATOLYMPHOID SYSTEM THIRD YEAR MEDICAL STUDENTS- UNIVERSITY OF JORDAN AHMAD T. MANSOUR, MD Part 4 MYELOID NEOPLASMS Introduction: o Myeloid neoplasms are divided into three major categories: o Acute
More informationMYELOPROLIFARATIVE NEOPLASMS. Dr. Hasan Fahmawi, MRCP(UK), FRCP(Edin).
MYELOPROLIFARATIVE NEOPLASMS Dr. Hasan Fahmawi, MRCP(UK), FRCP(Edin). These are a group of chronic conditions characterised by clonal proliferation of marrow precursor cells. PRV, essential thrombocyathaemia,
More informationPublished Ahead of Print on January 31, 2014, as doi: /haematol Copyright 2014 Ferrata Storti Foundation.
Published Ahead of Print on January 31, 2014, as doi:10.3324/haematol.2013.101733. Copyright 2014 Ferrata Storti Foundation. The International Prognostic Scoring System does not accurately discriminate
More informationVirtually every intracellular signal transduction
MYELOPROLIFERATIVE DISORDERS Therapeutic potential of JAK2 inhibitors Srdan Verstovsek 1 1 The University of Texas M. D. Anderson Cancer Center, Houston, TX The discovery of an activating tyrosine kinase
More informationHypereosinophili c syndrome
Hypereosinophili c syndrome Eosinophilia Eosinophilia is commonly defined as an elevated percentage of eosinophils, with an absolute eosinophil count > 500 cells per cubic millimeter Secondary Primary
More informationShould Mutation Status in PMF Guide Therapy? No! Brady L. Stein, MD MHS Assistant Professor of Medicine Division of Hematology/Oncology
Should Mutation Status in PMF Guide Therapy? No! Brady L. Stein, MD MHS Assistant Professor of Medicine Division of Hematology/Oncology Case presentation A 67 yo woman presents to transition care, as her
More informationMyeloproliferative neoplasia: a review of clinical criteria and treatment
REVIEW Myeloproliferative neoplasia: a review of clinical criteria and treatment S.M. Koopmans* 1, A.M.W. van Marion 2, H.C. Schouten 3 1 Department of Pathology of the University Hospital Maastricht,
More informationDisclosures for Ayalew Tefferi
Disclosures for Ayalew Tefferi Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Janssen, Geron, Celgene, Sanofi-Aventis, Gilead Sciences, Incyte
More informationJAK2 V617F analysis. Indication: monitoring of therapy
JAK2 V617F analysis BCR-ABL genotyping The exact chromosomal defect in Philadelphia chromosome is a translocation. Parts of two chromosomes, 9 and 22, switch places. The result is a fusion gene, created
More informationRelated Policies None
Medical Policy MP 2.04.60 BCBSA Ref. Policy: 2.04.60 Last Review: 07/25/2018 Effective Date: 07/25/2018 Section: Medicine Related Policies None DISCLAIMER Our medical policies are designed for informational
More informationINTRODUCTION TO CYTOGENETICS AND MOLECULAR TESTING IN MDS
INTRODUCTION TO CYTOGENETICS AND MOLECULAR TESTING IN MDS Saturday, September 29, 2018 Cyrus C. Hsia, HBSc, MD, FRCPC Associate Professor of Medicine, Schulich School of Medicine and Dentistry, Western
More informationHematopoietic Cell Transplantation for Myelofibrosis. Outline
Hematopoietic Cell Transplantation for Myelofibrosis H.Joachim Deeg MD Fred Hutchinson Cancer Research Center & University of Washington, Seattle WA Great Debates, NY, 4/28/2012 Outline Rationale for hematopoietic
More informationRuben A. Mesa, MD & John Camoranio, MD Mayo Clinic
Arizona, USA Prognosis & MPN Management in 2013 Ruben A. Mesa, MD & John Camoranio, MD Mayo Clinic Arizona, USA Understanding MPN Therapy Options Prognosis and Goals (Mesa & Camoriano) Evolving Rx ET (Vannucchi)
More informationMolecular aberrations in MPN. and use in the clinic. Timothy Devos MD PhD
Molecular aberrations in MPN and use in the clinic Timothy Devos MD PhD MB&C2017 24-3-2017 Introduction 1951: William Dameshek MPD MPN = clonal, hematopoietic stem cell disorders, proliferation in BM of
More informationClinical trials with JAK inhibitors for essential thrombocythemia and polycythemia vera
Clinical trials with JAK inhibitors for essential thrombocythemia and polycythemia vera Alessandro M. Vannucchi, MD Laboratorio Congiunto MMPC Department of Experimental and Clinical Medicine University
More informationJ Clin Oncol 29: by American Society of Clinical Oncology INTRODUCTION
VOLUME 29 NUMBER 4 FEBRUARY 1 11 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates
More information